299.45

1.57% -4.78

Pre-market: 301.10 1.65 +0.55%

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Financials Why KRYS Down? Discussions Forecast

Krystal Biotech Inc stock is traded at $299.45, with a volume of 162.21K. It is down -1.57% in the last 24 hours and up +8.52% over the past month. Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Previous Close:

$304.23

Open:

$305.1

24h Volume:

162.21K

Relative Volume:

0.57

Market Cap:

$8.83B

Revenue:

$389.13M

Net Income/Loss:

$204.83M

P/E Ratio:

43.75

EPS:

6.8443

Net Cash Flow:

$188.91M

1W Performance:

-2.23%

1M Performance:

+8.52%

6M Performance:

+41.24%

1Y Performance:

+139.01%

1-Day Range:

$297.18

$309.41

1-Week Range:

$286.00

$309.41

52-Week Range:

$122.80

$319.48

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1106)

Industry

Biotechnology (618)

Phone

(412) 586-5830

Address

2100 WHARTON STREET, PITTSBURGH, PA

Employee

295

Twitter

@KrystalBiotech

Next Earnings Date

2026-05-04

Latest SEC Filings

KRYS's Discussions on Twitter

Compare KRYS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRYS Krystal Biotech Inc	299.45	8.97B	389.13M	204.83M	188.91M	6.8443
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-26	Initiated	Wolfe Research	Peer Perform
Jan-06-26	Upgrade	Citigroup	Neutral → Buy
Mar-05-25	Initiated	Jefferies	Buy
Aug-06-24	Downgrade	Citigroup	Buy → Neutral
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

May 25, 2026

Krystal Biotech (KRYS) Investor Outlook: Robust Growth Prospects with 8.32% Potential Upside - DirectorsTalk Interviews

May 25, 2026

Precision Trading with Krystal Biotech Inc. (KRYS) Risk Zones - Stock Traders Daily

May 25, 2026

May 23, 2026

Krystal Biotech Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus

May 23, 2026

May 22, 2026

BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $364 - Moomoo

May 22, 2026

KRYS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $310 - GuruFocus

May 22, 2026

KRYS Technical Analysis | Trend, Signals & Chart Patterns | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill

May 22, 2026

May 21, 2026

Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end - MSN

May 21, 2026

May 20, 2026

Krystal Biotech, Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results - Minichart

May 20, 2026

Krystal Biotech Shareholders Approve Directors and Compensation - TipRanks

May 20, 2026

May 19, 2026

The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability - Sahm

May 19, 2026

Krystal Biotech Inc stock (US5012681064): HC Wainwright confirms Buy as UK clears VYJUVEK - AD HOC NEWS

May 19, 2026

May 18, 2026

Krystal Biotech gains regulatory approval to sell gene therapy in the United Kingdom - The Business Journals

May 18, 2026

Krystal Biotech Q1 earnings & sales beat estimates, pipeline in focus - MSN

May 18, 2026

Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com - Investing.com South Africa

May 18, 2026

Krystal Biotech receives UK approval for gene therapy VYJUVEK - Investing.com

May 18, 2026

Krystal Biotech's (KRYS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

May 18, 2026

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times

May 18, 2026

First UK genetic medicine for DEB lets some patients treat wounds at home - Stock Titan

May 18, 2026

Krystal Biotech Price Target Maintained With a $310.00/Share by HC Wainwright & Co. - Moomoo

May 18, 2026